292 related articles for article (PubMed ID: 34651291)
21. [
Watts A; Singh B; Singh H; Bal A; Kaur H; Dhanota N; Arora SK; Mittal BR; Behera D
Eur J Nucl Med Mol Imaging; 2023 Mar; 50(4):1216-1227. PubMed ID: 36482077
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic efficacy of C-X-C motif chemokine receptor 4-directed PET/CT in newly diagnosed head and neck squamous cell carcinoma - a head-to-head comparison with [
Zhi Y; Werner RA; Schirbel A; Higuchi T; Buck AK; Kosmala A; Bley TA; Hagen R; Hackenberg S; Rosenwald A; Scherzad A; Gerhard-Hartmann E; Serfling SE
Am J Nucl Med Mol Imaging; 2023; 13(5):208-216. PubMed ID: 38023816
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic value of [ 68 Ga]Ga-Pentixafor versus [ 18 F]FDG PET/CTs in non-small cell lung cancer: a head-to-head comparative study.
Mirshahvalad SA; Manafi-Farid R; Fallahi B; Seifi S; Geramifar P; Emami-Ardekani A; Eftekhari M; Beiki D
Nucl Med Commun; 2023 Sep; 44(9):803-809. PubMed ID: 37334548
[TBL] [Abstract][Full Text] [Related]
24. The potential utility of [
Lan L; Liu H; Wang Y; Deng J; Peng D; Feng Y; Wang L; Chen Y; Qiu L
Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):963-979. PubMed ID: 34410435
[TBL] [Abstract][Full Text] [Related]
25. Chemokine Receptor 4-Targeted 68Ga-Pentixafor PET/CT in Response Assessment of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: Comparison to 18F-FDG PET/CT.
Pan Q; Cao X; Luo Y; Li J; Li F
Clin Nucl Med; 2021 Sep; 46(9):732-737. PubMed ID: 34172595
[TBL] [Abstract][Full Text] [Related]
26. Immunohistochemical detection of chemokine receptor 4 expression in chronic osteomyelitis confirms specific uptake in 68Ga-Pentixafor-PET/CT.
Bouter Y; Meller B; Sahlmann CO; Wolf BJ; Langer L; Bankstahl JP; Wester HJ; Kropf S; Meller J; Bouter C
Nuklearmedizin; 2018 Sep; 57(5):198-203. PubMed ID: 30267402
[TBL] [Abstract][Full Text] [Related]
27. Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [
Haug AR; Leisser A; Wadsak W; Mitterhauser M; Pfaff S; Kropf S; Wester HJ; Hacker M; Hartenbach M; Kiesewetter-Wiederkehr B; Raderer M; Mayerhoefer ME
Theranostics; 2019; 9(12):3653-3658. PubMed ID: 31281504
[TBL] [Abstract][Full Text] [Related]
28. CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas.
Weich A; Werner RA; Buck AK; Hartrampf PE; Serfling SE; Scheurlen M; Wester HJ; Meining A; Kircher S; Higuchi T; Pomper MG; Rowe SP; Lapa C; Kircher M
Diagnostics (Basel); 2021 Mar; 11(4):. PubMed ID: 33805264
[TBL] [Abstract][Full Text] [Related]
29. Chemokine Receptor CXCR4-Targeted PET/CT With 68Ga-Pentixafor Shows Superiority to 18F-FDG in a Patient With Waldenström Macroglobulinemia.
Luo Y; Pan Q; Feng J; Cao X; Li F
Clin Nucl Med; 2018 Jul; 43(7):548-550. PubMed ID: 29742593
[TBL] [Abstract][Full Text] [Related]
30. Prognostic significance of
Kuyumcu S; Isik EG; Tiryaki TO; Has-Simsek D; Sanli Y; Buyukkaya F; Özkan ZG; Kalayoglu-Besisik S; Unal SN
Ann Nucl Med; 2021 Oct; 35(10):1147-1156. PubMed ID: 34185263
[TBL] [Abstract][Full Text] [Related]
31. 68 Ga-Pentixafor PET/CT for In Vivo Imaging of CXCR4 Receptors in Glioma Demonstrating a Potential for Response Assessment to Radiochemotherapy: Preliminary Results.
Waheed A; Singh B; Watts A; Kaur H; Singh H; Dhingra K; Ahuja C; Madan R; Singh A; Radotra BD
Clin Nucl Med; 2024 Apr; 49(4):e141-e148. PubMed ID: 38350065
[TBL] [Abstract][Full Text] [Related]
32. The Role of [
Albano D; Dondi F; Bertagna F; Treglia G
Cancers (Basel); 2022 Aug; 14(15):. PubMed ID: 35954476
[TBL] [Abstract][Full Text] [Related]
33. Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [
Serfling SE; Lapa C; Dreher N; Hartrampf PE; Rowe SP; Higuchi T; Schirbel A; Weich A; Hahner S; Fassnacht M; Buck AK; Werner RA
Mol Imaging Biol; 2022 Aug; 24(4):659-665. PubMed ID: 35312939
[TBL] [Abstract][Full Text] [Related]
34. Usefulness of 68 Ga-Pentixafor PET/CT on Diagnosis and Management of Cushing Syndrome.
Ding J; Tong A; Hacker M; Feng M; Huo L; Li X
Clin Nucl Med; 2022 Aug; 47(8):669-676. PubMed ID: 35452014
[TBL] [Abstract][Full Text] [Related]
35. First Experience with Chemokine Receptor CXCR4-Targeted PET Imaging of Patients with Solid Cancers.
Vag T; Gerngross C; Herhaus P; Eiber M; Philipp-Abbrederis K; Graner FP; Ettl J; Keller U; Wester HJ; Schwaiger M
J Nucl Med; 2016 May; 57(5):741-6. PubMed ID: 26769866
[TBL] [Abstract][Full Text] [Related]
36.
Bouter C; Meller B; Sahlmann CO; Staab W; Wester HJ; Kropf S; Meller J
J Nucl Med; 2018 Feb; 59(2):320-326. PubMed ID: 28729430
[TBL] [Abstract][Full Text] [Related]
37. Functional nodules in primary aldosteronism: identification of CXCR4 expression with
Gao Y; Ding J; Cui Y; Li T; Sun H; Zhao D; Zhang Y; Huo L; Tong A
Eur Radiol; 2023 Feb; 33(2):996-1003. PubMed ID: 36070092
[TBL] [Abstract][Full Text] [Related]
38. 68Ga-Pentixafor PET/MRI for Treatment Response Assessment in Mantle Cell Lymphoma: Comparison Between Changes in Lesion CXCR4 Expression on PET and Lesion Size and Diffusivity on MRI.
Mayerhoefer ME; Raderer M; Weber M; Lamm W; Kiesewetter B; Hacker M; Nics L; Schmitl S; Leithner D; Wester HJ; Haug A
Clin Nucl Med; 2023 Jul; 48(7):557-562. PubMed ID: 37272977
[TBL] [Abstract][Full Text] [Related]
39. [
Li X; Yu W; Wollenweber T; Lu X; Wei Y; Beitzke D; Wadsak W; Kropf S; Wester HJ; Haug AR; Zhang X; Hacker M
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(8):1616-1625. PubMed ID: 31004184
[TBL] [Abstract][Full Text] [Related]
40. Chemokine Receptor 4-Targeted PET/CT With 68 Ga-Pentixather Detects More Lesions Than 68 Ga-Pentixafor PET/CT in Multiple Myeloma.
Yang Q; Zhang F; Hao Z; Zhuang J; Huo L
Clin Nucl Med; 2024 Jun; 49(6):592-593. PubMed ID: 38630995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]